Product Name :
Inarigivir
Description:
Inarigivir (ORI-9020;SB-9000) is a dinucleotide which can significantly reduce liver HBV DNA in transgenic mice expressing hepatitis B virus.
CAS:
475650-36-3
Molecular Weight:
587.50
Formula:
C20H26N7O10PS
Chemical Name:
[(2R,3S,5R)-5-(6-amino-9H-purin-9-yl)-3-hydroxyoxolan-2-yl]methyl (2R,3R,4R,5R)-5-(2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl)-2-(hydroxymethyl)-4-methoxyoxolan-3-yl sulfanylphosphonate
Smiles :
CO[C@H]1[C@@H](O[C@H](CO)[C@H]1OP(=O)(S)OC[C@H]1O[C@H](C[C@@H]1O)N1C=NC2C(N)=NC=NC1=2)N1C=CC(=O)NC1=O
InChiKey:
LYMICVBGNUEHGE-FUQPUAIBSA-N
InChi :
InChI=1S/C20H26N7O10PS/c1-33-16-15(10(5-28)36-19(16)26-3-2-12(30)25-20(26)31)37-38(32,39)34-6-11-9(29)4-13(35-11)27-8-24-14-17(21)22-7-23-18(14)27/h2-3,7-11,13,15-16,19,28-29H,4-6H2,1H3,(H,32,39)(H2,21,22,23)(H,25,30,31)/t9-,10+,11+,13+,15+,16+,19+,38?/m0/s1
Purity:
≥98% (or refer to the Certificate of Analysis)
Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition :
Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.{{Edoxaban} site|{Edoxaban} Metabolic Enzyme/Protease|{Edoxaban} Technical Information|{Edoxaban} Data Sheet|{Edoxaban} manufacturer|{Edoxaban} Epigenetics}
Shelf Life:
≥12 months if stored properly.{{Topotecan} web|{Topotecan} Apoptosis|{Topotecan} Technical Information|{Topotecan} In stock|{Topotecan} manufacturer|{Topotecan} Epigenetics}
Stock Solution Storage:
0 – 4 oC for 1 month or refer to the Certificate of Analysis.
Additional information:
Inarigivir (ORI-9020;SB-9000) is a dinucleotide which can significantly reduce liver HBV DNA in transgenic mice expressing hepatitis B virus.|Product information|CAS Number: 475650-36-3|Molecular Weight: 587.50|Formula: C20H26N7O10PS|Chemical Name: [(2R,3S,5R)-5-(6-amino-9H-purin-9-yl)-3-hydroxyoxolan-2-yl]methyl (2R,3R,4R,5R)-5-(2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl)-2-(hydroxymethyl)-4-methoxyoxolan-3-yl sulfanylphosphonate|Smiles: CO[C@H]1[C@@H](O[C@H](CO)[C@H]1OP(=O)(S)OC[C@H]1O[C@H](C[C@@H]1O)N1C=NC2C(N)=NC=NC1=2)N1C=CC(=O)NC1=O|InChiKey: LYMICVBGNUEHGE-FUQPUAIBSA-N|InChi: InChI=1S/C20H26N7O10PS/c1-33-16-15(10(5-28)36-19(16)26-3-2-12(30)25-20(26)31)37-38(32,39)34-6-11-9(29)4-13(35-11)27-8-24-14-17(21)22-7-23-18(14)27/h2-3,7-11,13,15-16,19,28-29H,4-6H2,1H3,(H,32,39)(H2,21,22,23)(H,25,30,31)/t9-,10+,11+,13+,15+,16+,19+,38?/m0/s1|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: DMSO : 200 mg/mL (340.PMID:23771862 43 mM; Need ultrasonic).|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.|Shelf Life: ≥12 months if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vivo:|I.p. injection of Inarigivir at 100 mg/kg/day significantly reduces viral DNA in the liver and shows anti-HBV activity similar ADV positive control. Serum HBV DNA is not reduced in response to treatment. Inarigivir does not affect levels of HBV RNA in liver, levels of HBeAg in serum, or mean titers of HBsAg. The minimal effective dose is identified to be between 1.6 and 0.5 mg/kg/day using liver HBV DNA values.|Products are for research use only. Not for human use.|